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The 4-aminoquinoline naphthoquine (NQ) and the thiazine dye methylene blue (MB) have potent in vitro efficacies against Plas-
modium falciparum, but susceptibility data for P. vivax are limited. The species- and stage-specific ex vivo activities of NQ and
MBwere assessed using a modified schizont maturation assay on clinical field isolates from Papua, Indonesia, where multidrug-
resistant P. falciparum and P. vivax are prevalent. Both compounds were highly active against P. falciparum (median [range]
50% inhibitory concentration [IC50]: NQ, 8.0 nM [2.6 to 71.8 nM]; andMB, 1.6 nM [0.2 to 7.0 nM]) and P. vivax (NQ, 7.8 nM [1.5
to 34.2 nM]; andMB, 1.2 nM [0.4 to 4.3 nM]). Stage-specific drug susceptibility assays revealed significantly greater IC50s in para-
sites exposed at the trophozoite stage than at the ring stage for NQ in P. falciparum (26.5 versus 5.1 nM, P 0.021) and P. vivax
(341.6 versus 6.5 nM, P 0.021) and for MB in P. vivax (10.1 versus 1.6 nM, P 0.010). The excellent ex vivo activities of NQ
and MB against both P. falciparum and P. vivax highlight their potential utility for the treatment of multidrug-resistant malaria
in areas where both species are endemic.
Early diagnosis and effective treatment of malaria are central tothe success of malaria control programs. However, this strat-
egy is compromised by the emergence of drug-resistant parasites
that are well established in Plasmodium falciparum and increas-
ingly recognized in P. vivax (1, 2). The emergence of multidrug-
resistant parasites throughout the regions of the world where ma-
laria is endemic has been a driving force in the development and
deployment of a variety of artemisinin-based combination thera-
pies (ACT) for the treatment of falciparummalaria (3). Endorsed
by the World Health Organization (WHO), ACT is now the first-
line antimalarial treatment in more than 80 countries. Although
chloroquine (CQ) remains the treatment of choice for vivax ma-
laria, this position is increasingly under threat from the emergence
and spread of CQ-resistant P. vivax strains that, in some areas,
have reached high levels, requiring the revision of national guide-
lines (2).
The ability of parasites to develop resistance to antimalarial
drugs is relentless, as evidenced by reports of the emergence and
spread of decreased in vivo and in vitro susceptibility to most an-
timalarial agents, including the artemisinin derivatives (4, 5) and
ACT (6, 7). It is imperative that the development of new and
effective partner drugs is maintained to ensure an armamentar-
ium of highly effective antimalarial treatments.
Naphthoquine phosphate (NQ), a 4-aminoquinoline com-
pound first synthesized in China in the 1980s, demonstrates ex-
cellent efficacy against the murine malaria parasite P. berghei and
CQ-resistant P. falciparum (8–10). NQ has been combined with
artemisinin as a fixed-dose combination therapy (ARCO) with
proven in vivo efficacy against falciparum (11–13) and vivax ma-
laria (14–16). Although approved and registered in more than 10
countries, in vitro NQ susceptibility data in clinical isolates of P.
falciparum are limited, with no published ex vivo data yet available
for P. vivax.
The antimalarial activity of the thiazine dye methylene blue
(MB) was first reported at the end of the 19th century (17).
Although MB’s antimalarial efficacy has been proven in several
studies over the next decades, MB was abandoned from the
drug development pipeline due to its low tolerability, which
was the result of unpleasant, but reversible, adverse effects (18).
There is renewed interest in the use of MB in the modern era of
malaria therapeutics, with studies highlighting its potent schi-
zonticidal activity against CQ-resistant P. falciparum (19–24)
and gametocytocidal activity (25–27). Furthermore, clinical
trials in Africa have shown that effective antiplasmodial doses
of MB are safe in both adults and children, including glucose-
6-phosphate dehydrogenase (G6PD)-deficient individuals (28,
29). MB has also been shown to have ex vivo activity against
CQ-sensitive P. vivax (30) but has yet to be assessed against
CQ-resistant P. vivax.
The objectives of the current study were to examine the spe-
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cies- and stage-specific ex vivo susceptibilities of NQ and MB in
clinical field isolates of Plasmodium from an area with known
multidrug resistance inP. falciparum andP. vivax and to define the
cross-susceptibility patterns between NQ and MB and conven-
tional antimalarials.
MATERIALS AND METHODS
Field location and sample collection. Plasmodium isolates were col-
lected from patients attending malaria clinics in Timika (Papua, Indo-
nesia), a region known to be endemic for P. falciparum isolates resistant
to CQ, amodiaquine (AQ), and sulfadoxine-pyrimethamine (SP), and
P. vivax isolates resistant to CQ (31–33). Unpublished clinical data
from 2015 suggest that dihydroartemisinin (DHA) and piperaquine
(PIP) retain high efficacy against both Plasmodium species. Patients
with symptomatic malaria were recruited into the study if they were
singly infected with P. falciparum or P. vivax, with a parasitemia of
between 2,000 l1 and 80,000 l1, and the majority (70%) of
parasites at the ring stage of development. After written consent was
obtained, venous blood samples (5 ml) were collected and after re-
moval of host white blood cells by using cellulose filters, the packed
infected red blood cells (iRBCs) were used for the ex vivo drug suscep-
tibility assay.
Ex vivo drug susceptibility assay.Drug plates were predosed with the
standard antimalarials CQ, AQ, PIP, mefloquine (MFQ), and artesunate
(AS) (WWARN QA/QC Reference Material Programme) (34) plus NQ
(MMV17; Swiss Tropical and Public Health Institute, Basel, Switzerland,
on behalf of Medicines for Malaria Venture [MMV]) and MB (Sigma-
Aldrich, Australia).
The drug susceptibility of P. vivax and P. falciparum isolates was
measured using a protocol modified from the WHO microtest as de-
scribed previously (33, 35, 36). In brief, 200 l of a 2% hematocrit
blood media mixture (BMM), consisting of RPMI 1640 medium plus
10% AB human serum (P. falciparum) or McCoy’s 5A medium plus
20% AB human serum (P. vivax) was added to each well of predosed
drug plates containing 11 serial concentrations (2-fold dilutions) of
the antimalarials (maximum concentration shown in parentheses) CQ
(2,993 nM), AQ (158 nM), PIP (1,029 nM), MFQ (338 nM), AS (49
nM), NQ (481 nM), and MB (51 nM). A candle jar was used to mature
the parasites at 37.0°C for 35 to 56 h. Incubation was stopped when
40% of the ring-stage parasites had reached the mature schizont
stage in the drug-free control wells.
Thick blood films made from each well were stained with 5% Giemsa
solution for 30 min and examined microscopically. The number of schi-
zonts per 200 asexual stage parasites was determined for each drug con-
centration and normalized to the control well.
To investigate the stage-specific drug susceptibility of antimalarial ac-
tion, a subgroup of isolates with 90% ring-stage parasites initially was
exposed to the drugs for 24 h. The iRBCs were then washed with phos-
TABLE 1 Baseline characteristics of isolates for which ex vivo assays were performed
Baseline characteristic
Naphthoquine Methylene blue
P. falciparum
(n 25)
P. vivax
(n 38)
P. falciparum
(n 63)
P. vivax
(n 50)
Isolates reaching harvest (no. [%]) 21 (84.00) 29 (76.32) 52 (82.54) 41 (82.00)
Delay from venepuncture to start of culture (median [range]) (min) 160 (85–310) 178 (55–330) 125 (60–310) 148 (55–330)
Duration of assay (median [range]) (h) 44 (32–48) 47 (42–50) 45 (32–50) 46 (32–50)
Parasitemia (geometric mean [95% CIa]) (asexual parasites/l) 24,102 25,001 13,343 22,454
(15,856–36,637) (17,487–35,742) (11,059–16,099) (16,531–30,501)
Parasites at ring stage initially (median [range]) (%) 100b 96 (71–99) 100b 96 (70–99)
Schizont count at harvest (mean [range]) (%) 50 (16–76) 45 (13–70) 42 (14–75) 43 (13–70)
a CI, confidence interval.
b No range given (all values were 100%).
TABLE 2 Ex vivo drug susceptibility for each drug according to the species tested
Drug
P. falciparum laboratory
linesa P. falciparum clinical field isolates P. vivax clinical field isolates
PbFC27 (CQs) K1 (CQr) No. (%)c Median (range) IC50 (nM) P
d No. (%)c Median (range) IC50 (nM) P
d
CQ 24.1 140.5 21 (100) 80.9 (10.9–158.7) 0.001 29 (100) 106.4 (9.0–334.6) 0.001 0.485
AQ 20.3 26.9 21 (100) 22.5 (4.6–54.2) 0.001 29 (100) 21.2 (8.8–49.2) 0.001 0.549
PIP 31.7 47.2 21 (100) 36.9 (10.6–121.2) 0.001 29 (100) 23.0 (3.5–51.9) 0.001 0.014
MFQ 53.8 13.7 21 (100) 19.0 (3.2–53.3) 0.030 29 (100) 16.8 (4.9–61.5) 0.001 0.791
AS 10.1 7.7 21 (100) 3.8 (0.8–15.7) [0.001] 29 (100) 1.8 (0.9–13.5) [0.001] 0.012
NQ 13.1 15.3 21 (100) 8.0 (2.6–71.8) 29 (100) 7.8 (1.5–34.2) 0.7015
CQ 16.3 121.4 52 (100) 93.7 (28.4–279.0) 0.001 41 (100) 146.0 (29.2–383.4) 0.001 0.001
AQ 14.2 21.3 50 (96) 13.7 (4.6–28.3) 0.001 40 (98) 23.4 (3.7–49.5) 0.001 0.001
PIP 45.9 38.1 52 (100) 25.0 (5.2–58.1) 0.001 40 (98) 21.5 (3.4–75.3) 0.001 0.440
MFQ 72.0 16.3 52 (100) 10.5 (2.8–38.0) 0.001 41 (100) 16.8 (2.4–81.4) 0.001 0.015
AS 9.7 5.1 51(100) 3.8 (0.7–31.0) 0.001 40 (98) 1.7 (0.4–19.7) 0.001 0.002
MB 7.2 5.7 51 (100) 1.6 (0.2–7.0) 40 (98) 1.2 (0.4–4.3) 0.001
a Mean IC50s (derived from three independent experiments) were assessed by in vitro schizont maturation quantified by microscopy. CQ
s, chloroquine-sensitive laboratory strain;
CQr, chloroquine-resistant laboratory strain.
b Significant difference in median drug IC50s between species (Wilcoxon rank sum test).
c Total number of assays with acceptable IC50s (percentage of samples which fulfilled the criteria for successful culture).
d Comparison of each drug (Wilcoxon rank sum test) with either NQ (top) or MB (bottom).
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phate-buffered saline using centrifugation andwere resuspended in drug-
free medium and cultured for another 20 to 24 h before harvest (i.e.,
ring-stage assay). The same isolate was cultured for 20 to 24 h in the
absence of drugs until 85 to 95% of parasites had reached the trophozoite
stage; these were then drug exposed for 24 h until harvest (trophozoite
stage assay) (33, 37).
Quality control procedures. Microscopy quality control was en-
sured by randomly selecting recordings for two drugs per isolate which
were read by a second microscopist. If the raw data derived by the two
microscopists led to a significant shift in the 50% inhibitory concen-
tration (IC50) estimates of the selected drugs (i.e., more than one di-
lution difference), the whole assay (i.e., all standard drugs and exper-
imental compounds) was reread by a second reader, and the results
were compared. Discrepant results were resolved by a third reading by
an expert microscopist. Drug plate quality was ensured by testing drug
plates using the samemethodology with P. falciparum laboratory strains
K1 and FC27.
Data analysis. The dose-response data were analyzed using nonlinear
regression analysis (WinNonlin 4.1; Pharsight Corporation), and the
IC50s were derived using an inhibitory sigmoid Emax model. Ex vivo IC50
data were only used from predicted curves where the maximum effect
(Emax) and E0 were within 15% of 100 and 1, respectively. Data analysis
was performed using STATA (version 13.1) andGraphPad Prism (version
6). TheMann-Whitney U test, Wilcoxon signed-rank test, and Spearman
rank correlation were used for nonparametric comparisons and correla-
tions.
FIG 1 Ex vivo drug susceptibility (median IC50s) to standard antimalarials, NQ (A) and MB (B) in P. falciparum (closed symbols) and P. vivax (open symbols)
clinical isolates (P, Wilcoxon rank sum test).
Naphthoquine and Methylene Blue Ex Vivo Susceptibility
October 2015 Volume 59 Number 10 aac.asm.org 6119Antimicrobial Agents and Chemotherapy
 o
n
 August 29, 2016 by CHARLES DARW
IN UNIVERSITY
http://aac.asm
.org/
D
ow
nloaded from
 
Ethical approval. Ethical approval for this study was obtained from the
Eijkman Institute Research Ethics Commission, the Eijkman Institute for
MolecularBiology, Jakarta, Indonesia, and theHumanResearchEthicsCom-
mittee of the Northern Territory (NT) Department of Health and Families
andMenzies School of Health Research, Darwin, Australia.
RESULTS
Drug susceptibility. A total of 147 clinical isolates from patients
with single-species infections of either P. falciparum (n 80) or P.
vivax (n  67) were assessed. The standard antimalarials were
assayed for all isolates and NQ was assayed in 63 isolates (25 P.
falciparum and 38 P. vivax) between June and October 2011 and
again between June and September 2013. MB was tested in 113
isolates (63 P. falciparum and 50 P. vivax) between January and
September 2013. NQ and MB were tested in parallel in only 8 P.
falciparum and 21 P. vivax isolates. Adequate growth for harvest
was achieved in 84% (21/25) of P. falciparum and 76% (29/38) of
P. vivax isolates in which NQ was tested and in 83% (52/63) of P.
falciparum and 82% (41/50) of P. vivax isolates in which MB was
tested. The baseline characteristics of the isolates processed are
presented in Table 1.
The IC50s for isolates which were successfully cultured and the
comparison with IC50s for P. falciparum laboratory strains FC27
and K1 are shown in Table 2 and Fig. 1. Although NQ and MB
were tested on different drug plate lots, quality control experi-
ments using laboratory strains and the same assaymethod showed
no differences between drug plate lots for either the standard an-
timalarials or the test compounds NQ and MB. In the MB group,
the median IC50s in P. falciparum were significantly higher than
those ofP. vivax for AS (3.8 versus 1.7 nM,P 0.002) andMB (1.6
versus 1.2 nM, P 0.001), but lower than those for CQ (93.7 nM
versus 146.0, P 0.001), AQ (13.7 versus 23.4 versus, P 0.001),
and MFQ (10.5 nM versus 16.8, P 0.015).
NQ showed very potent activities against both species (8.0 nM
in P. falciparum and 7.8 nM in P. vivax), and its activity was sig-
nificantly higher than the activities of all of the standard antima-
larials tested, with the exception of AS. MB exhibited excellent
activities (median IC50s of 1.6 nM against P. falciparum and 1.2
nM against P. vivax), exceeding the activities of all standard anti-
malarials tested, including the artemisinin derivative AS (Table 2;
Fig. 1).
Stage-specific drug activity. In P. vivax isolates, the median
IC50s of all drugs were significantly higher at the trophozoite
stage than at the ring stage, the ratio being 1.5- to 8-fold higher
for the standard antimalarials and MB and 50-fold higher for
NQ (Table 3 and Fig. 2). The difference in stage specificity was
much less in P. falciparum isolates, with significance reached only
for PIP (21.9 nM for rings versus 128.2 nM for trophozoites; P
0.045) and NQ (5.1 nM versus 26.5 nM; P 0.021).
Cross-susceptibility patterns. Growth inhibition by NQ was
strongly correlated in P. falciparum and P. vivax isolates with AQ,
PIP, and MFQ but only with CQ in P. vivax and with AS in P.
falciparum isolates (Table 4). ForMB,moderate correlations were
observed for CQ, AQ, PIP, andMFQ in P. falciparum but not in P.
vivax isolates.
DISCUSSION
The current study highlights the potent ex vivo activities of NQ
and MB against multidrug-resistant isolates of P. falciparum and
P. vivax. The IC50s of NQ in P. falciparum isolates (median IC50,
8.0 nM; interquartile range, 26.5 nM) were similar to those re-
ported in culture-adapted P. falciparum isolates from Papua New
Guinea (geometricmean, 7.0; 95% confidence interval [CI], 5.5 to
8.8 nM) (38). Our ex vivo study presents additional evidence for
NQ’s potent activities against highly CQ-resistant isolates of P.
falciparum and P. vivax, revealing lower IC50s for NQ than for all
of the standard drugs with the exception of AS. The ex vivo activity
of MB was greater than that of NQ, in line with previous observa-
tions in P. falciparum (19–24, 39) and P. vivax (30), with lower
IC50s than those for all standard drugs, including AS, for both
species.
Interspecies comparisons of drug susceptibilities revealed
slightly different patterns in the two subgroups of isolates. Al-
though these observations might suggest underlying species dif-
ferences in pharmacodynamic activity, the differences were of
marginal magnitude and may also reflect statistical chance.
Positive correlations of drug susceptibilities are potentially in-
dicative of either similar modes of action of these drugs or similar
pharmacokinetic properties. Alternatively, they can represent ac-
quired resistance on the background of previous antimalarial re-
sistance phenotypes. Previous studies of P. falciparum have docu-
mented positive correlations between the IC50s for the quinoline
class of compounds and related drugs (38, 40). The correlation of
NQwith AQ, PIP,MFQ, and AS observed in P. falciparum isolates
in the present studywas similar to that reported fromneighboring
PapuaNewGuinea (38). Surprisingly, we observed no correlation
between NQ and CQ IC50s in P. falciparum. However, in P. vivax
isolates, NQ IC50s were positively correlated with those of all the
quinoline-based drugs, but not AS. In contrast, the only signifi-
TABLE 3 Ex vivo susceptibilities for paired isolates exposed for 24 h at the ring and trophozoite stages
Drug
P. falciparum P. vivax
No.a
Median (range) IC50 (nM)
Pb No.a
Median (range) IC50 (nM)
PbRings Trophozoites Rings Trophozoites
CQ 6 107.9 (60.2–163.6) 142.7 (25.5–163.6) 0.855 11 81.7 (27.6–190.2) 705.6 (99.9–4,033.3) 0.001
AQ 7 16.2 (4.9–20.8) 18.0 (7.8–25.4) 0.570 11 20.0 (2.1–39.5) 47.7 (7.6–89.8) 0.031
PIP 6 21.9 (7.8–33.3) 128.2 (13.8–359.3) 0.045 11 18.0 (3.5–69.6) 30.3 (18.1–204.5) 0.042
MFQ 7 15.3 (4.7–46.9) 17.3 (4.6–30.6) 0.570 11 21.4 (4.9–41.0) 34.9 (11.7–85.5) 0.042
AS 6 2.1 (0.7–5.1) 3.9 (1.3–8.1) 0.584 11 1.9 (0.9–5.7) 7.2 (0.8–19.3) 0.045
NQ 4 5.1 (2.5–7.0) 26.5 (16.6–36.5) 0.021 4 6.5 (4.0–18.8) 341.6 (150.8–622.6) 0.021
MB 4 4.1 (3.1–6.9) 4.4 (3.5–6.8) 0.773 6 1.6 (0.6–3.7) 10.1 (1.9–36.5) 0.010
a Number of paired isolates.
b Comparison of drugs tested at the ring and trophozoite stages.
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cant correlations for MB were with CQ, AQ, and PIP in P. falcip-
arum, a pattern similar to that observed in previous studies (22,
24).MB’s parasitocidal activity is postulated to bemediated by the
inhibition of heme polymerization (39, 41) and glutathione re-
ductase in P. falciparum (42, 43). Assuming a similar mode of
cytotoxicity in P. vivax, the contrasting correlation most likely
indicates differences in drug uptake and partition between the two
species.
Weobserved amarked stage-specific action forNQ.Compared
to parasites at the ring stage, the trophozoites of bothP. falciparum
and P. vivax were resistant to NQ, with 5-fold and 50-fold higher
IC50s, respectively. The stage specificity was less apparent for MB,
only reaching significance for P. vivax trophozoites, which had
6-fold higher IC50s than ring stages. The findings for NQ are at
odds with previous data for other conventional antimalarials such
as CQ and AQ, which manifest a far greater difference in stage-
specific activity for P. vivax, although the number of isolates tested
was small (33, 37). Further studies are needed to validate these
findings and investigate the phenomenon of innate versus ac-
quired drug tolerance in Plasmodium.
FIG 2 Ex vivo drug susceptibility (median IC50s) for NQ (A) and MB (B) according to the species tested and for paired ring-stage (closed symbols) versus
trophozoite-stage (open symbols) parasites (P, Wilcoxon rank sum test).
Naphthoquine and Methylene Blue Ex Vivo Susceptibility
October 2015 Volume 59 Number 10 aac.asm.org 6121Antimicrobial Agents and Chemotherapy
 o
n
 August 29, 2016 by CHARLES DARW
IN UNIVERSITY
http://aac.asm
.org/
D
ow
nloaded from
 
The potent NQ ex vivo activity demonstrated against both P.
falciparum and P. vivax suggests that NQmay be a suitable candi-
date as an ACT partner drug in regions where these species are
coendemic. NQ combined with artemisinin derivatives has
achieved adequate clinical efficacy against falciparum malaria
(11–13), as well as against CQ-sensitive and CQ-resistant vivax
malaria (14–16). However, concerns have been raised that the
currently available single-dose regimen (ARCO) provides inade-
quate reduction of the early parasite biomass, leaving the more
slowly eliminated NQ vulnerable to the selection of drug resis-
tance. Our data demonstrate a correlation in antimalarial activity
with that of the other 4-aminoquinolines and, together with a
report of the induction of NQ resistance in an experimental ro-
dent model (8), highlight the importance of close monitoring of
drug efficacy, particularly in areas where quinoline-based ACTs
have been in widespread use.
The current study also confirms MB’s remarkable ex vivo effi-
cacy against resistant strains ofP. falciparum andP. vivax, showing
high potency, a broad stage specificity of action, including game-
tocyte stages (25), and synergism with other antimalarials (19, 21,
44). Although researchers and drug developers have been aware of
the antimalarial properties of MB against P. falciparum for almost
a century, it has never been widely used in clinical practice, largely
due to its poor tolerability profile. Its side effects include head-
aches, nausea, and discoloration of urine and sclera, all of which
are reversible. Neurotoxicity andmutagenicity have also been ob-
served in animal models (45). However, recent clinical studies
have demonstrated MB’s ability to elicit an adequate cure for P.
falciparum infectionwith acceptable tolerability in young children
(46, 47), and MB plasma levels have been shown to be safe at
concentrations 10-fold higher than the IC50s observed in our ex
vivo experiments (48). In areas where artemisinin resistance is
emerging, the partner drugs in combination therapies are under
increasing pressure for the selection of resistance and the thera-
peutic agents available are limited. In this context, the utility of
MB in the treatment of multidrug-resistant malaria warrants fur-
ther investigation.
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